Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antipsychotic Response to Clozapine in B-SNIP Biotype-1
NCT04580134Phase 4Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2022
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clozapine in schizophrenia, schizoaffective disorder and bipolar I disorder (4 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Positive and Negative Syndrome Scale at 18 weeks. Started Mar 2022; status: recruiting.
02
Drugs
clozapine
03
Conditions
schizophreniaschizoaffective disorderbipolar I disorder
Beyond the preview
Go deeper on NCT04580134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580134.